IGC Pharma expands Phase 2 CALMA trial to University of South Florida

IGC Pharma (IGC) announced the expansion of its ongoing Phase 2 CALMA clinical trial evaluating investigational drug candidate IGC-AD1 for agitation in Alzheimer’s disease. The trial has officially opened a new site at the University of South Florida’s Department of Psychiatry and Behavioral Neurosciences, under the leadership of Principal Investigator Dr. Ram Bishnoi. Enrollment at the new site has already begun, with four participants enrolled, marking an important step toward accelerating recruitment and advancing the timeline of the study. The addition of USF, a leading research and academic institution, underscores IGC Pharma’s commitment to partnering with distinguished investigators to address the urgent, unmet needs of patients living with Alzheimer’s disease.